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Abstract
Parkinson’s disease (PD) without (non-demented, PDND) and with dementia (PDD), and dementia with Lewy bodies (DLB)
are subsumed under the umbrella term Lewy body disorders (LBD). The main component of the underlying pathologic
substrate, i.e. Lewy bodies and Lewy neurites, is misfolded alpha-synuclein (Asyn), and - in particular in demented LBD
patients - co-occurring misfolded amyloid-beta (Abeta). Lowered blood and cerebrospinal fluid (CSF) levels of transthyretin
(TTR) - a clearance protein mainly produced in the liver and, autonomously, in the choroid plexus - are associated with
Abeta accumulation in Alzheimer’s disease. In addition, a recent study suggests that TTR is involved in Asyn clearance. We
measured TTR protein levels in serum and cerebrospinal fluid of 131 LBD patients (77 PDND, 26 PDD, and 28 DLB) and 72
controls, and compared TTR levels with demographic and clinical data as well as neurodegenerative markers in the CSF. Five
single nucleotide polymorphisms of the TTR gene which are considered to influence the ability of the protein to carry its
ligands were also analyzed. CSF TTR levels were significantly higher in LBD patients compared to controls. Post-hoc analysis
demonstrated that this effect was driven by PDND patients. In addition, CSF TTR levels correlated negatively with CSF
Abeta1–42, total tau and phospho-tau levels. Serum TTR levels did not significantly differ among the studied groups. There
were no relevant associations between TTR levels and genetic, demographic and clinical data, respectively. These results
suggest an involvement of the clearance protein TTR in LBD pathophysiology, and should motivate to elucidate TTR-related
mechanisms in LBD in more detail.
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Introduction
The term ‘‘Lewy body disorders (LBD)’’ subsumes the three
entities Parkinson’s disease (PD) without dementia (PDND), PD
with dementia (PDD), and dementia with Lewy bodies (DLB) [1].
In LBD, alpha-synuclein (Asyn)-positive Lewy bodies (LB) and
Lewy neurites occur together with neurodegeneration [2].
Moreover, co-occurrence of amyloid-beta (Abeta) deposits with
Asyn pathology is common, particularly in LBD patients with
dementia [3,4]. It is widely accepted that an Abeta1–42 production
higher than its removal results in an enhanced presence of Abeta1–
42 monomers, oligomers, insoluble fibrils and plaques in the
central nervous system [5]. Age, ApoE genotype [6] as well as
proteins and metabolites such as apolipoprotein E [7], apolipo-
protein J (clusterin) [8], apolipoprotein A1 [9], uric acid [10],
neprilysin [11], tau proteins [12], cystatin C [13], and transthy-
retin [14,15] play a role in the neurotoxic aggregation of the
usually soluble form of Abeta1–42. Similar mechanisms may lead to
Asyn accumulation, at least for late onset PD although there is less
evidence for this hypothesis [16].
The transthyretin (TTR) gene is located at chromosome 18q11
and consists of four exons [17]. TTR is mainly synthesized in the
liver and the epithelial cells of the choroid plexus [18]. Recent
results indicate that it is also a neuronal product up-regulated in
Alzheimer’s disease (AD) [19]. It has binding sites for retinol
binding protein (RBP), thyroxin and also for Abeta1–42 [20]. It can
influence Abeta1–42 aggregation and destroy already formed
Abeta1–42 fibrils by proteolytic cleavage of the peptides [21]. It
has been suggested that TTR may be one of the major Abeta1–42-
binding and -sequestering proteins in human cerebrospinal fluid
(CSF) [14,15]. Increased production of TTR in neurons exposed
to Abeta1–42 toxicity, and reduced levels of the protein in blood
[22,23] and CSF [24–26] indicate an involvement of TTR
(dys)function in clearance deficits as they occur in AD. In addition,
there is very recent - at least indirect - evidence that TTR may be
involved in Asyn clearance. Guerreiro and colleagues [27]
observed highly increased levels of monomeric and oligomerized
Asyn in the saliva of symptomatic heterozygous V30M TTR
mutation carriers suffering from familial amyloidosis compared to
healthy control individuals. Interestingly, Asyn levels in saliva of
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symptomatic TTR mutation carriers who underwent orthotropic
liver transplantation (and, consecutively, had non-mutated TTR)
were comparable with those of controls.
It has been demonstrated that not only the relatively rare
mutations but also common variants of the TTR gene are
differentially capable of altering the ability of TTR to carry and
transport its ligands [28]. This has been shown in particular for the
TTR single nucleotide polymorphisms (SNPs) rs13381522 and
rs3764478 (both lie at the 5`end in the promoter region of the TTR
gene), rs1800458 (located in exon 2, leads to a non-synonymous
amino acid exchange of glycin to serin on position 26 of the TTR
nucleotide sequence), rs723744 (localized in intron 3, does not
result in amino acid differences), and rs36204272 (is intronic and
spliced posttranslationally, should have no effect on the TTR
protein) [15,29–31]. As LBD patients obviously show neuronal
and neural clearance deficits comparable to AD [16] and TTR
seems to be critically involved in these mechanisms, we
hypothesized that blood and CSF levels of TTR are altered in
LBD patients and may be associated with clinical and demo-
graphic data, and that occurrence of the abovementioned SNPs
are associated with these TTR levels.
Study Participants, Material and Methods
Ethics Statement
The study was approved by the ethics committee of the Medical
Faculty, University of Tuebingen, Germany, and was performed
according to the principles expressed in the Declaration of
Helsinki. All participants gave their written informed consent. In
case of compromised capacity of the participants to consent
(MMSE ,18 points), or another person was named to make
decisions on behalf of the person, responsible persons consented
on the behalf of the participant.
Study Participants
Demented DLB, PDD and non-demented LBD patients
(PDND), and elderly neurodegeneratively healthy control individ-
uals (HC) were recruited from the ward and the outpatient clinic of
the Neurodegenerative Department of the University of Tuebin-
gen. LBD patients were diagnosed based on clinical criteria by
specialists in the field of neurodegenerative movement disorders
(DB, TG, WM). All PD patients fulfilled the UKPDS Brain Bank
criteria [32]. PDD patients, in addition, met the Diagnostic and
Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for
dementia as well as core and associated clinical features proposed
by Emre and colleagues [33]. All DLB patients fulfilled the
McKeith criteria for clinical diagnosis of probable DLB [34].
Control individuals underwent spinal taps for exclusion of vascular
events or inflammatory conditions. Any clinical sign for a
neurodegenerative disorder led to exclusion from the study.
All individuals underwent demographic analysis and clinical
testing including a Hoehn&Yahr (H&Y) staging and a Mini-
Mental State Examination (MMSE). Table 1 provides an overview
of demographic, clinical, and biochemical data of the groups.
Cerebrospinal Fluid and Serum Collection
CSF and serum collection as well as determination of routine
diagnostic parameters were performed according to standardized
protocols (for details see [35]). We only used samples specifically
dedicated to this project from our biobank (http://www.hih-
tuebingen.de/de/nd/biobank/for-researchers/), without any pre-
vious freeze-thaw cycle. Our biobank fulfills highest international
standards with regard to collection, preparation and storage of
biosamples. Samples for determination of TTR levels were
centrifuged (CSF: 4000 g, 4uC, 10 min; blood: 2000 g, 4uC,
10 min) and stored at 280uC within 60 minutes after collection
until analysis. Only samples of patients with normal routine CSF
diagnostics were included in the study, slightly increased CSF
albumin levels (up to 450 mg/L) were tolerated.
TTR, Abeta1–42, Total Tau and Phospho-tau Measurement
TTR levels in CSF and serum were measured using a laser
nephelometric method with Ics Pab Prealbumin Reagent Test Kit
on Beckman Coulter IMMAGEH Immunochemistry Systems
according to manufacturer’s instructions (Beckman Coulter
GmbH, Krefeld, Germany). Samples were run in triplicate. We
observed within run precision of ,2.0% coefficient of variation
(CV), and total precision of ,5% CV.
CSF Abeta1–42, total tau and phospho-tau levels were deter-
mined using commercially available ELISA kits (Innogenetics NV,
Ghent, Belgium).
TTR and ApoE Genotyping
Genomic DNA was extracted using standard protocols. The
coding sequence of the TTR gene was determined with Sanger-
sequencing technique to identify the SNPs rs1800458 and
rs36204272. SNPs rs13381522, rs3764478, and rs723744 which
are located at the TTR intron or promoter region were analyzed
by the SNaPshot method. Briefly, a PCR with specific SNaPshot
primers was performed. After single base extension with fluores-
cent-labeled ddNTPs the SNaPshot product was analyzed by
capillary gel electrophoresis with ABI Prism 3100 Genetic
Analyzer sequencer (Applied Biosystems Life Technologies
GmbH, Darmstadt, Germany). Fluorescence data were analyzed
using Gene Mapper v3.5.
ApoE genotypes were obtained by PCR amplification of exon 4
of the ApoE gene, and subsequent digestion with enzyme HhaI
according to [36]. All SNPs investigated were in Hardy-Weinberg
equilibrium.
Data Analysis
Data were analyzed with JMP software (version 9.0.2, SAS). As
dementia associated with LBD may per se be a relevant factor
associated with TTR levels, PDD and DLB were not only
considered as single groups but also comprised as a PDD/DLB
group (see Table S1 for details). Demographic and clinical data
were analyzed with the Wilcoxon signed rank test (LBD versus
controls; presented as median and range) or Fishers exact test. As
age was significantly different between LBD and controls and as
there is some evidence that serum TTR may be associated with
age [37], we corrected both serum and CSF TTR levels for this
covariate using a regression model. The coefficient of determina-
tion (r2) was used as a measure for the proportion of response
variation which was explained by the regressors in the model.
Significance of each model effect was assessed by the likelihood
ratio.
Differences were considered significant at p,0.05. Post-hoc
analyses (TTR levels of PDND versus controls, PDND versus
demented LBD, controls versus demented LBD) were corrected
for multiple testing (see Table 2 and Table S1 for details).
Results
TTR Levels and Demographic Variables
TTR values in CSF and serum were normally distributed, and
did not correlate. They were not age-related, neither in CSF
(controls, r2 = 0.02, p=0.88; LBD patients, r2 = 0.01, p=0.64) nor
in serum (controls, r2 = 0.01, p=0.19; LBD patients, r2 = 0.02,
Transthyretin in Lewy Body Disorders
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Table 1. Demographic, clinical, and routine biochemical data.
LBD Controls p-value
PDND PDD DLB
Individuals (f/m) [n] 131 (59/72) 72 (34/38) 0.88
77 (34/43) 26 (11/15) 28 (14/14)
Age [years]: all 70 (44–84) 57 (40–80) ,.0001
68 (44–81) 71 (62–84) 74 (50–83)
females 70 (44–84) 57 (43–79) ,.0001
68 (44–80) 71 (64–84) 76 (50–83)
males 69 (46–84) 58 (40–80) ,.0001
68 (46–81) 71 (62–84) 71 (58–78)
Aao parkinsonism [years] 63 (30–79)
62 (30–79) 63 (51–74) 70 (49–78)
Duration of parkinsonism
[years]
4.6 (0.1–25.0)
4.1 (0.1–25.0) 8.7 (3.7–21.4) 2.9 (0.9–13.2)
Aao dementia [years] 69 (49–79)
69 (58–79) 70 (49–79)
Duration dementia [years] 2.8 (0.4–12.2)
2.1 (0.4–5.9) 3.4 (0.5–12.2)
H&Y stage (1–5) [n] 2.5 (1.0–4.5 )
2 (1–4) 3 (2–5) 3 (1–4)
MMSE (0–30) 27 (10–30) 30 (27–30) ,.0001
29 (25–30) 21 (13–29) 19 (10–27)
ApoE4 [%] 34 15 0.047
33 23 45
CSF amyloid-beta1–42 [pg/ml] 595 (134–1458) 907 (264–1446) ,.0001
629 (134–1458) 497 (147–851) 453 (228–1241)
CSF total tau [pg/ml] 199 (25–1074) 183 (32–868) 0.56
176 (25–1074) 254 (48–660) 236 (77–596)
CSF phospho-tau [pg/ml] 40 (12–127) 39 (14–158) 0.39
36 (15–127) 57 (12–109) 50 (22–86)
Demographic, clinical, and biochemical data of patients with Lewy body disorders (LBD) and controls, presented with median (range). P-values were determined using
the Wilcoxon rank sum test, or the Fisher’s exact test. Aao, age at onset; ApoE4, Apolipoprotein E4; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; f, female;
H&Y, Hoehn&Yahr stage; m, male; MMSE, Mini-Mental State Examination; PDD, Parkinson’s disease with dementia; PDND, Parkinson’s disease non-demented.
doi:10.1371/journal.pone.0048042.t001
Table 2. Transthyretin values of the investigated cohorts.
LBD Controls p-value
PDND PDD DLB
CSF TTR [mg/dl] 1.73 (0.58–2.84) 1.58 (0.58–2.61) 0.037
1.80 (0.58–2.32) 1 1.60 (0.58–2.84) 1.68 (0.58–2.68)
Serum TTR [mg/dl] females 25.3 (12.1–39.8) 27.3 (19.6–48.1) 0.39
26.7 (16.1–39.8) 21.9 (15.5–30.1) 20.8 (12.1–31.7)
males 29.7 (15.2–46.5) 31.3 (19.9–43.9) 0.54
31.2 (17.0–46.5) 25.6 (15.2–35.1) 30.9 (21.7–37.1)
Transthyretin (TTR) levels were calculated using a regression model with age as a covariate. As serum TTR levels were significantly different between females and males
(see text) these values were calculated separately. P-values ,0.05 between patients with Lewy body disorders (LBD) and controls were considered significant. Post-hoc
analyses were performed for comparison of TTR levels between the following cohorts: Parkinson’s disease non-demented (PDND), Parkinson’s disease with dementia
(PDD), dementia with Lewy bodies (DLB), controls, PDD versus DLB, PDD versus controls, and DLB versus controls, with p-values ,0.01 (0.05/5 groups) considered
significant. CSF, cerebrospinal fluid.
doi:10.1371/journal.pone.0048042.t002
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p=0.11). CSF TTR values were approx. 18-fold lower than serum
values (1.7 versus 30.1 mg/dl).
Gender did not differ significantly between LBD patients and
controls. CSF TTR values were comparable between females and
males (controls, p=0.56; LBD patients, p=0.59). Serum TTR
levels were significantly higher in males than in females (controls,
p=0.03; LBD patients, p=0.002) and were therefore calculated
separately.
TTR Levels and LBD-associated Parameters
An overview is given in Table 2. CSF TTR values were
significantly higher in LBD patients (1.73 mg/dl) compared to
controls (1.58 mg/dl). The post-hoc analysis demonstrated that,
within the LBD group, PDND patients accounted for this effect
(1.80 mg/dl, r2 = 0.07, p = 0.008 compared to controls). Serum
TTR levels were not significantly different between LBD patients
and controls, and among LBD patients (see also Table S1).
CSF and serum TTR values were neither significantly
associated with clinical parameters (age at onset of parkinsonism,
duration of parkinsonism, Hoehn&Yahr stage, age at onset of
dementia, duration of dementia, MMSE score), nor with ApoE
status.
TTR Levels and Neurodegenerative Markers
There were weak but significant negative correlations between
CSF TTR values and respective levels of CSF Abeta1–42 (r
2 = 0.03,
p=0.02), CSF total tau (r2 = 0.03, p=0.02) and CSF phospho-tau
(r2 = 0.03, p=0.03). No significant correlations were detectable
between serum TTR values and neurodegenerative markers.
TTR Genotypes
None of the analyzed TTR SNPs (rs723744, rs13381522,
rs3764478, rs1800458 and rs36204272) showed a significant
association with LBD occurrence. In addition, no relevant
associations of the SNPs with demographical, clinical and
biochemical parameters were detectable (data not shown).
Discussion
In this study investigating TTR values in blood and CSF of
LBD patients, CSF TTR levels were significantly higher in this
cohort of patients compared to controls. The effect was mainly
driven by non-demented LBD patients, explaining, as a diagnosis,
approximately 7 percent of the variation in the CSF TTR levels.
This makes it tempting to speculate that Asyn pathology alone
(PDND patients rarely have marked additional brain pathology
such as leucoaraiosis [38,39] and Abeta1–42 pathology [4,23,40])
induces expression of central TTR. This observation may be
explained by the known occurrence of oxidative stress in LBD
[35,41], as CSF TTR values have been observed to rise in
response to oxidative stress [14]. In addition, an involvement of
TTR in inflammatory processes - a common feature observed in
brains of patients suffering from LBD - has also been suggested
[42]. In the light of previous reports which mainly found decreased
CSF TTR levels in disorders that are not primarily associated with
inflammation (i.e., depression [43], AD [14,24] and amyotrophic
lateral sclerosis [44]), but increased levels in disorders typically
associated with inflammatory processes (such as Guillain Barre´
syndrome and chronic inflammatory demyelinating polyneurop-
athy [45–47]) it may be interesting to focus in future studies on
putative interaction pathways between inflammation and TTR in
Asyn-associated pathology.
Actually it is not entirely clear whether (misfolded) Asyn is a
target protein of TTR. The latter mainly functions as a transport
protein, and is able to transfer e.g. Abeta1–42, as a misfolded
peptide, from the neuron to the CSF [25]. A recent study also
showed that Abeta1–42-stressed neurons increase the expression of
TTR [48]. Thus it is intriguing to hypothesize that Asyn is also a
target protein of TTR, and TTR may have an influence on Asyn-
associated pathology. Indeed, indirect evidence for this suggestion
comes from a recent study investigating levels of monomeric and
oligomeric Asyn in saliva using MALDI-TOFTOF MSMS ion
search and Western blotting [27]. In this study, symptomatic
individuals with a heterozygous V30M mutation in TTR had
much more intense Asyn-positive bands and a higher number of
such bands at higher molecular mass (indicative of oligomeric
forms of Asyn) than had control individuals and, most interest-
ingly, TTR mutation carriers who underwent orthotropic liver
transplantation. This strongly indicates that TTR is associated
with clearance of (misfolded) Asyn.
Interestingly, demented LBD patients had relatively low CSF
TTR levels, comparable to controls [49]. This is exciting in the
light of recent studies demonstrating decreased CSF TTR levels in
AD patients [14,24], and the regular occurrence of Abeta1–42
pathology in demented LBD patients. Together with the
observation that PDND patients have increased CSF TTR levels
one may hypothesize that demented LBD patients face two driving
forces with regard to TTR-associated pathways: Asyn pathology
which goes along with increased TTR expression, and Abeta1–42
pathology associated with decreased TTR expression. Based on
the abovementioned associations between TTR levels and amyloid
pathology, one can also hypothesize that increased TTR levels in
the brain protect against Abeta1–42 pathology. Indeed, there is
accumulating evidence from in-vitro and in-vivo studies that TTR
has beneficial direct and indirect effects on Abeta-associated
pathology (reviewed in [14]).
Serum TTR levels were not significantly different between LBD
patients and controls. Post-hoc analyses demonstrated slightly
reduced TTR levels in demented compared to non-demented
LBD patients. Although results did not survive correction for
multiple testing, they may motivate to future, hypothesis-driven
studies focusing on this particular aspect as decreased serum TTR
levels have already been described in AD patients [22,23,50],, and
are regarded as a biochemical marker for malnutrition [25,51] and
inflammation [52].
We found weak but significant negative correlations between
CSF TTR levels and the three actually best-established neurode-
generative markers in CSF, i.e. Abeta1–42, total tau and phospho-
tau. Together with the observed lack of such an association
between peripheral TTR and these neurodegenerative markers,
the observations may point to a specific interaction of central TTR
with LBD-associated amyloid clearance. Higher CSF TTR levels
were observed in non-demented LBD patients who regularly show
relatively low CSF tau levels [53,54]. This argues for an
interaction of TTR with the specific neurodegenerative process
(total tau) and axonal pathology (phospho-tau). The negative
correlation between TTR and Abeta1–42 CSF levels is somehow
counterintuitive and more difficult to explain as, in individuals
with Abeta1–42 pathology, CSF Abeta1–42 is regularly low and tau
parameters are high. Under physiological conditions, CSF TTR
binds Abeta1–42 and keeps it soluble especially in CSF [25].
Decreased CSF TTR values may indicate that this dynamic
equilibrium is affected, leading to accumulation and aggregation of
Abeta1–42 proteins, amyloid formation, and neurotoxicity [15].
Analysis of SNPs that have been shown to influence binding
capacity of TTR to amyloid did not add relevant information in
this study. This may be due to sample size, but also to the fact that
rather the absolute quantity of TTR than its function may be
Transthyretin in Lewy Body Disorders
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associated with LBD pathophysiology. Interestingly, we also did
not find a significant association between demographic and clinical
parameters (except the above reported, diagnosis of LBD and
occurrence of dementia), and TTR values. This may indicate that
TTR, although obviously involved in amyloidogenic and clear-
ance pathways in LBD, cannot serve as a marker of disease
progression and severity.
In conclusion, data presented in this study argue for a role of
TTR in both Asyn- and Abeta1–42-associated LBD pathologies.
The obvious interaction of centrally produced TTR with
pathophysiological mechanisms in these neurodegenerative pro-
cesses should motivate to more in-depth analyses.
Supporting Information
Table S1 Post-hoc analyses of transthyretin levels between
different groups
(DOC)
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